Medium impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota·Effective Mar 17, 2026
HCPCS C9172 is officially defined as "Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose." HCPCS C9172 is referenced in 1 tracked payer policy change from Blue Cross Blue Shield of North Dakota. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9172 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.